{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:11:18Z","timestamp":1748405478693,"version":"3.41.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Paediatric patients undergoing haemodialysis typically require intravenous (IV) iron therapy to replenish iron stores. Upon establishing our home haemodialysis service, the need for an efficient IV iron administration method prompted exploration beyond the conventional use of iron sucrose, which is associated with anaphylaxis and requires frequent infusions. Ferric carboxymaltose has a favourable safety profile and corrects iron deficiency with less frequent infusions. We aimed to establish if ferric carboxymaltose was a viable alternative in this patient group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This single-centre, uncontrolled retrospective cohort study assessed the effectiveness of ferric carboxymaltose in maintaining laboratory parameters (haemoglobin level, transferrin saturation and reticulocyte haemoglobin content) within target range in our home haemodialysis population. Secondly, we conducted a comparative analysis to establish maintenance efficacy of ferric carboxymaltose, versus iron sucrose over a 12-month period. Finally, we performed a cost-effectiveness analysis of IV iron therapy, considering cost per dose and per month of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Following ferric carboxymaltose infusion, we observed significant increases in haemoglobin level, transferrin saturation and reticulocyte haemoglobin content, which was maintained at 3-month post-infusion. Ferric carboxymaltose demonstrated comparable efficacy to iron sucrose in maintaining laboratory parameters. Strikingly, ferric carboxymaltose treatment was associated with significantly decreased number of infusions per month (~\u2009tenfold) and a significant cost-saving (~\u2009fivefold).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study underscores the clinical efficacy and economic benefits of ferric carboxymaltose as a viable treatment for iron deficiency anaemia in paediatric patients who are haemodialysis-dependent and highlights the potential for significant improvements in healthcare delivery, in terms of reducing frequency of hospital visits for this patient population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00467-025-06680-x","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T07:47:18Z","timestamp":1740815238000},"page":"2353-2361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A cost-effective innovation in anaemia management for paediatric patients with haemodialysis-dependent chronic kidney disease"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3971-6028","authenticated-orcid":false,"given":"Rebecca","family":"Preston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetria","family":"Theodorou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Sinnott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amrit","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"6680_CR1","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00467-010-1538-6","volume":"25","author":"MA Atkinson","year":"2010","unstructured":"Atkinson MA, Martz K, Warady BA, Neu AM (2010) Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS. Pediatr Nephrol 25:1699\u20131706","journal-title":"Pediatr Nephrol"},{"key":"6680_CR2","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1053\/j.ajkd.2006.03.010","volume":"47","author":"KDOQI; National Kidney Foundation","year":"2006","unstructured":"KDOQI; National Kidney Foundation (2006) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47:S11-145","journal-title":"Am J Kidney Dis"},{"key":"6680_CR3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/j.ajkd.2004.08.024","volume":"44","author":"A Gerson","year":"2004","unstructured":"Gerson A, Hwang W, Fiorenza J et al (2004) Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 44:1017\u20131023","journal-title":"Am J Kidney Dis"},{"key":"6680_CR4","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00467-017-3721-5","volume":"32","author":"HS Baek","year":"2017","unstructured":"Baek HS, Kang HG, Choi HJ et al (2017) Health-related quality of life of children with pre-dialysis chronic kidney disease. Pediatr Nephrol 32:2097\u20132105","journal-title":"Pediatr Nephrol"},{"key":"6680_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1681\/ASN.2011111115","volume":"23","author":"MM Mitsnefes","year":"2012","unstructured":"Mitsnefes MM (2012) Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23:578\u2013585","journal-title":"J Am Soc Nephrol"},{"key":"6680_CR6","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","volume":"23","author":"JL Babitt","year":"2012","unstructured":"Babitt JL, Lin HY (2012) Mechanisms of anemia in CKD. J Am Soc Nephrol 23:1631\u20131634","journal-title":"J Am Soc Nephrol"},{"key":"6680_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ajh.24201","volume":"91","author":"M Auerbach","year":"2016","unstructured":"Auerbach M, Adamson JW (2016) How we diagnose and treat iron deficiency anemia. Am J Hematol 91:31\u201338","journal-title":"Am J Hematol"},{"key":"6680_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","volume":"71","author":"S Fishbane","year":"2018","unstructured":"Fishbane S, Spinowitz B (2018) Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. Am J Kidney Dis 71:423\u2013435","journal-title":"Am J Kidney Dis"},{"key":"6680_CR9","doi-asserted-by":"publisher","first-page":"967233","DOI":"10.3389\/fped.2022.967233","volume":"10","author":"P Garcia-Ortega","year":"2022","unstructured":"Garcia-Ortega P, Jimenez-Lozano I, Cruz \u00c1 et al (2022) Safety and effectiveness of ferric carboxymaltose intravenous therapy in pediatric patients with chronic kidney disease. Front Pediatr 10:967233","journal-title":"Front Pediatr"},{"key":"6680_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/ckj\/sfz153","volume":"14","author":"J Portol\u00e9s-P\u00e9rez","year":"2021","unstructured":"Portol\u00e9s-P\u00e9rez J, Dur\u00e1-G\u00farpide B, Merino-Rivas JL et al (2021) Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: an observational study. Clin Kidney J 14:174\u2013180","journal-title":"Clin Kidney J"},{"key":"6680_CR11","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1093\/ndt\/gfq069","volume":"25","author":"A Covic","year":"2010","unstructured":"Covic A, Mircescu G (2010) The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant 25:2722\u20132730","journal-title":"Nephrol Dial Transplant"},{"key":"6680_CR12","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC, Bock AH, Carrera F et al (2014) FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 29:2075\u20132084","journal-title":"Nephrol Dial Transplant"},{"key":"6680_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40264-020-01022-2","volume":"44","author":"H Trumbo","year":"2021","unstructured":"Trumbo H, Kaluza K, Numan S, Goodnough LT (2021) Frequency and associated costs of anaphylaxis- and hypersensitivity-related adverse events for intravenous iron products in the USA: an analysis using the US Food and Drug Administration Adverse Event Reporting System. Drug Saf 44:107\u2013119","journal-title":"Drug Saf"},{"key":"6680_CR14","doi-asserted-by":"publisher","first-page":"e224488","DOI":"10.1001\/jamanetworkopen.2022.4488","volume":"5","author":"AH Arastu","year":"2022","unstructured":"Arastu AH, Elstrott BK, Martens KL et al (2022) Analysis of adverse events and intravenous iron infusion formulations in adults with and without prior infusion reactions. JAMA Netw Open 5:e224488\u2013e224488","journal-title":"JAMA Netw Open"},{"key":"6680_CR15","first-page":"137","volume":"17","author":"S G\u00f3mez-Ram\u00edrez","year":"2019","unstructured":"G\u00f3mez-Ram\u00edrez S, Shander A, Spahn DR et al (2019) Prevention and management of acute reactions to intravenous iron in surgical patients. Blood Transfus 17:137\u2013145","journal-title":"Blood Transfus"},{"key":"6680_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","volume":"89","author":"IC Macdougall","year":"2016","unstructured":"Macdougall IC, Bircher AJ, Eckardt KU et al (2016) Iron management in chronic kidney disease: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference. Kidney Int 89:28\u201339","journal-title":"Kidney Int"},{"key":"6680_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","volume":"90","author":"T Avni","year":"2015","unstructured":"Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A (2015) The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 90:12\u201323","journal-title":"Mayo Clin Proc"},{"key":"6680_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/ndt\/gfi253","volume":"21","author":"GM Chertow","year":"2006","unstructured":"Chertow GM, Mason PD, Vaage-Nilsen O, Ahlm\u00e9n J (2006) Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 21:378\u2013382","journal-title":"Nephrol Dial Transplant"},{"key":"6680_CR19","doi-asserted-by":"publisher","first-page":"e24571","DOI":"10.1097\/MD.0000000000024571","volume":"100","author":"HW Shin","year":"2021","unstructured":"Shin HW, Go DY, Lee SW, Choi YJ, Ko EJ, You HS, Jang YK (2021) Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: a systematic review and meta-analysis. Medicine (Baltimore) 100:e24571","journal-title":"Medicine (Baltimore)"},{"key":"6680_CR20","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1007\/s00431-022-04582-w","volume":"181","author":"A Aksan","year":"2022","unstructured":"Aksan A, Zepp F, Anand S, Stein J (2022) Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review. Eur J Pediatr 181:3781\u20133793","journal-title":"Eur J Pediatr"},{"key":"6680_CR21","unstructured":"National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management., London. Available from: https:\/\/www.nice.org.uk\/guidance\/ng203\/resources\/chronic-kidney-disease-assessment-and-management-pdf-66143713055173. Accessed 9 Sept 2024"},{"key":"6680_CR22","unstructured":"Paediatric Formulary Committee (2022) British National Formulary for Children. Available from: https:\/\/bnfc.nice.org.uk\/.\u00a0Accessed 10 Sept 2024"},{"key":"6680_CR23","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00431-017-2995-8","volume":"176","author":"MLN Tan","year":"2017","unstructured":"Tan MLN, Windscheif PM, Thornton G, Gaynor E, Rodrigues A, Howarth L (2017) Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre. Eur J Pediatr 176:1419\u20131423","journal-title":"Eur J Pediatr"},{"key":"6680_CR24","unstructured":"Health Products Regulatory Authority. Ferric carboxymaltose 50 mg iron\/ml dispersion for injection\/infusion. Summary of product characteristics. Available from: https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/Licence_PA0949-004-001_08062023091120.pdf. Accessed 9 Sept 2024"},{"key":"6680_CR25","unstructured":"U.S. Food and Drug Administration. Ferric carboxymaltose; Clinical review. Available from: https:\/\/www.fda.gov\/media\/156642\/download.\u00a0Accessed 9 Sept 2024"},{"key":"6680_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12882-019-1263-8","volume":"20","author":"M Diebold","year":"2019","unstructured":"Diebold M, Kistler AD (2019) Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing. BMC Nephrol 20:76","journal-title":"BMC Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06680-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06680-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06680-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T09:17:47Z","timestamp":1748337467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06680-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6680"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06680-x","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"type":"print","value":"0931-041X"},{"type":"electronic","value":"1432-198X"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}